AC Immune Statistics
Total Valuation
AC Immune has a market cap or net worth of $193.88 million. The enterprise value is $109.97 million.
Important Dates
The last earnings date was Wednesday, November 4, 2026, before market open.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AC Immune has 99.43 million shares outstanding. The number of shares has increased by 2.58% in one year.
| Current Share Class | 99.43M |
| Shares Outstanding | 99.43M |
| Shares Change (YoY) | +2.58% |
| Shares Change (QoQ) | -36.05% |
| Owned by Insiders (%) | 5.71% |
| Owned by Institutions (%) | 4.43% |
| Float | 39.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 17.17 |
| PS Ratio | 8.16 |
| Forward PS | 22.00 |
| PB Ratio | 4.06 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.85, with a Debt / Equity ratio of 0.14.
| Current Ratio | 0.85 |
| Quick Ratio | 0.80 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -166.53 |
Financial Efficiency
Return on equity (ROE) is -80.66% and return on invested capital (ROIC) is -48.24%.
| Return on Equity (ROE) | -80.66% |
| Return on Assets (ROA) | -23.20% |
| Return on Invested Capital (ROIC) | -48.24% |
| Return on Capital Employed (ROCE) | -90.99% |
| Weighted Average Cost of Capital (WACC) | 12.93% |
| Revenue Per Employee | $194,657 |
| Profits Per Employee | -$354,172 |
| Employee Count | 122 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.50% in the last 52 weeks. The beta is 1.61, so AC Immune's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -37.50% |
| 50-Day Moving Average | 2.43 |
| 200-Day Moving Average | 2.63 |
| Relative Strength Index (RSI) | 36.00 |
| Average Volume (20 Days) | 242,944 |
Short Selling Information
The latest short interest is 2.95 million, so 6.34% of the outstanding shares have been sold short.
| Short Interest | 2.95M |
| Short Previous Month | 3.26M |
| Short % of Shares Out | 6.34% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 14.73 |
Income Statement
In the last 12 months, AC Immune had revenue of $23.75 million and -$43.21 million in losses. Loss per share was -$0.42.
| Revenue | 23.75M |
| Gross Profit | -27.43M |
| Operating Income | -45.31M |
| Pretax Income | -43.21M |
| Net Income | -43.21M |
| EBITDA | -43.66M |
| EBIT | -45.31M |
| Loss Per Share | -$0.42 |
Full Income Statement Balance Sheet
The company has $88.59 million in cash and $4.67 million in debt, with a net cash position of $83.92 million or $0.84 per share.
| Cash & Cash Equivalents | 88.59M |
| Total Debt | 4.67M |
| Net Cash | 83.92M |
| Net Cash Per Share | $0.84 |
| Equity (Book Value) | 32.29M |
| Book Value Per Share | 0.48 |
| Working Capital | -18.05M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$60.08 million and capital expenditures -$706,770, giving a free cash flow of -$60.79 million.
| Operating Cash Flow | -60.08M |
| Capital Expenditures | -706,770 |
| Depreciation & Amortization | 1.63M |
| Net Borrowing | -1.14M |
| Free Cash Flow | -60.79M |
| FCF Per Share | -$0.61 |
Full Cash Flow Statement Margins
Gross margin is -115.49%, with operating and profit margins of -190.79% and -181.95%.
| Gross Margin | -115.49% |
| Operating Margin | -190.79% |
| Pretax Margin | -181.95% |
| Profit Margin | -181.95% |
| EBITDA Margin | -183.86% |
| EBIT Margin | -190.79% |
| FCF Margin | n/a |
Dividends & Yields
AC Immune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.58% |
| Shareholder Yield | -2.58% |
| Earnings Yield | -21.50% |
| FCF Yield | -31.35% |
Analyst Forecast
The average price target for AC Immune is $8.36, which is 328.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.36 |
| Price Target Difference | 328.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 211.24% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AC Immune has an Altman Z-Score of -4.29 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.29 |
| Piotroski F-Score | 2 |